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CHAPTER 1: Introduction 
The gut microbiota and colorectal cancer 
The human microbiota is the collection of microorganisms that live in and on the human 
body. Only recently has the scientific community begun to appreciate the important 
roles that these bacteria, archaea, viruses, and fungi and other eukaryotes play in 
regulating human health. The gastrointestinal tract is the most densely populated part of 
the human body, and one of the highest densities of microbial life on the planet [1]. This 
diverse collection of organisms harbors an even more diverse catalog of genes that 
encode for roughly 100 times more unique genes than the human genome. This 
functional diversity allows the gut microbiota to compliment its host in a number of ways, 
including synthesis of vitamins, degradation of resistant starches, immune system 
maturation, and resistance to pathogens [2–5]. Due to its important role in human 
health, disruptions to the microbiota have been associated with a variety of diseases, 
such as Crohn’s disease, ulcerative colitis, enteric infections, diabetes, obesity, 
malnutrition, and of particular interest to this dissertation, colorectal cancer (CRC) [5–9]. 
A growing body of evidence has demonstrated that the gut microbiota plays an 
important role in CRC. The gut microbiota is known to influence cancer-related functions 
like cell proliferation, angiogenesis, and apoptosis [10–12]. It is also linked to diet, 
obesity and inflammatory bowel disease, which are known risk factors of CRC [6, 8, 13–
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15]. Moreover, at least thirty studies in the past decade have identified alterations in the 
microbiota associated with CRC [16]. Animal models have shown that cancer-
associated changes in the microbiota can promote tumorigenesis, and that several 
bacterial species are capable of promoting colon tumorigenesis on their own [9, 17–19]. 
Microbiota composition influences tumorigenesis 
To better understand the role of the microbiota in CRC, our lab turned to a chemically 
induced mouse model of colitis-associated CRC. In this model, mice are given a single 
intraperitoneal injection of the carcinogen azoxymethane (AOM), followed by three five-
day rounds of 2% dextran sulfate sodium (DSS) administered ad libitum in the drinking 
water. This model works well because it is quick and the mutations and tumor 
progression mirror those of human CRC [20, 21]. Our lab hypothesized that the 
community as a whole, more so than any one species, is responsible for modulating 
colon tumorigenesis. Using the AOM/DSS mouse model, we observed shifts in the 
composition of the microbiota during tumorigenesis [9]. To test whether such shifts 
influenced tumorigenesis, tumor-associated or normal stool was transferred to germ-
free mice that were then subjected to AOM/DSS treatment. Mice inoculated with the 
tumor-associated microbiota developed significantly more tumors than those inoculated 
with a healthy microbiota [9]. This phenotype occurred in the absence of any known 
tumorigenic pathogens and suggested that the microbiota could modulate 
tumorigenesis. More recently, we showed that manipulation of the microbiota using 
different combinations of antibiotics could vary the number of tumors mice developed, 
and a three-antibiotic cocktail of vancomycin, streptomycin, and metronidazole could all 
but block tumorigenesis entirely [22]. Furthermore, we could predict the number of 
	 3	
tumors mice would develop based on the composition of the microbiota during antibiotic 
treatment. These findings suggested that the composition of the microbiota influences 
susceptibility to tumorigenesis. 
Using antibiotics to manipulate the microbiota is limited in two important ways. First, 
treating mice with antibiotics primarily alters the abundance of populations already 
present in the community. Membership should be less affected, especially for mice 
living in an isolated environment in which they are exposed to a limited number of 
species. Second, antibiotics can directly impact the immune system of the host, 
independent of the microbiota [23]. This could in turn influence tumorigenesis. To 
address these concerns while further investigating how the composition of the 
microbiota influences tumorigenesis, we turned to a germ-free mouse model. Chapter 2 
of this dissertation describes an experiment in which germ-free mice were inoculated 
with stool from one of six human donors and then subjected to the AOM/DSS model of 
CRC [24]. This method allowed us to study highly distinct microbiota structures without 
the confounding effects of antibiotics. Furthermore, it allowed us to investigate microbial 
populations of human origin, which are likely of greater clinical relevance. The findings 
from that study demonstrated that the initial composition of the microbiota may influence 
an individual’s susceptibility to CRC. 
CRC Screening 
The observation that microbiota composition differs in patients with CRC opens up the 
possibility of using shifts in the microbiota as a biomarker of tumor development. Early 
detection of tumors is key for CRC prevention and treatment. Patient’s in whom CRC is 
detected at stage I, have greater than 90% of survival, whereas patients in whom 
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tumors are detect at stage IV have less than 13% chance of survival [25]. Great 
progress has been made in reducing CRC incidence and mortality through increased 
surveillance, yet CRC remains the second leading cause of death among cancers in the 
United States [26]. This is due in part to a continued lack of adherence to screening 
guidelines, as a third of individuals fail to receive appropriate screening [27]. Screening 
adherence is drastically lower among those who are uninsured, suggesting that cost is 
one barrier to screening [27, 28]. Patients also commonly cite fear and/or discomfort as 
deterrents to undergo structural exams like colonoscopy and sigmoidoscopy [29]. 
Therefore, there is a need for screening alternatives that are inexpensive and 
noninvasive. 
For many years the most common noninvasive screening method for CRC was the 
guaiac-based fecal occult blood test (gFOBT), which detects blood in stool. The gFOBT 
is largely being replaced by the newer more accurate fecal immunochemical test (FIT), 
which also detects blood, but is specific to the human globin protein [30]. Both gFOBT 
and FIT are inexpensive and noninvasive, however neither is able to reliably detect 
early stage tumors, particularly precancerous adenomas. The relatively new multitarget 
DNA test (MT-sDNA) combines FIT with host-associated DNA markers (i.e. KRAS 
mutations, aberrant methylation patterns, β-actin) and has improved sensitivity 
compared to FIT or gFOBT [31]. Unfortunately MT-sDNA is much more expensive than 
FIT or gFOBT, costing as much as $649 in out-of-pocket expenses 
(http://www.cologuardtest.com/what-to-expect-with-cologuard/faq/cologuard-cost-how-
much-is-cologuard). Thus, there remains a need for inexpensive, noninvasive tests that 
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can reliably detect early stage tumors. The microbiota could potentially be source of 
biomarkers for such a test. 
Individual species as biomarkers of CRC 
Many bacteria have been associated with CRC, but only a few have been shown to be 
potential drivers of tumorigenesis. One such bacterium is enterotoxigenic Bacteroides 
fragilis (ETBF). ETBF differs from other B. fragilis strains by the secretion of a toxin, 
called fragilysin. ETBF is capable of promting Wnt/β-catenin signaling by cleaving E-
cadherin, inducing NF-κB signaling, and initiating a Th17 immune response, all of which 
enhance colon tumorigenesis [17, 32]. Inoculation of APCMin/+ mice with ETBF results in 
accelerated tumorigenesis and shifts the location of tumors from the small intestine to 
the distal colon [17]. Evidence for ETBF as a biomarker for CRC is limited, but one 
study detected the fragilysin gene in Bacteroides isolates from the stool of 38% of CRC 
patients compared to 12% of controls [33]. Another study isolated Bacteroides from 
mucosal samples and found that fragilysin positive isolates were more common in CRC 
patients compared to controls [34]. However, both studies were limited by having a 
small numbers of patients and by relying on culturing isolates for detection. 
Similar to ETBF, certain strains of E. coli may have the potential to promote colon 
tumorigenesis. Some E. coli harbor a polyketide synthase (pks) genotoxic pathogenicity 
island, which is capable of causing DNA double-stranded breaks in eukaryotic cells. 
Arthur et al. showed that pks+ E. coli increased DNA damage and increased tumor 
multiplicity in Il10-/- mice treated with AOM [18]. Deletion of the pks island reduced DNA 
damage and tumor multiplicity, but not inflammation. In the same study, they isolated 
the pks+ E. coli in 14 of 21 CRC patients and 14 of 35 IBD patients, compared to 5 of 24 
	 6	
controls, suggesting pks+ E. coli could be a marker of CRC or colonic inflammation in 
general. 
In the many studies comparing the microbiota of healthy individuals to those with CRC, 
Fusobacterium nucleatum is the most commonly enriched species in CRC patients. 
Kostic et al. found multiple Fusobacterium species enriched in colorectal carcinoma 
tissue biopsies relative to adjacent healthy tissue [35] and an enrichment of F. 
nucleatum in the stool of patients with colorectal adenomas relative to healthy controls 
[19]. They went on to show that F. nucleatum can accelerate small intestinal 
tumorigenesis in APCMin/+ mice via recruitment of myeloid cells and activation of NF-κB. 
Concurrently Rubinstein et al. found that binding of the F. nucleatum adhesion FadA to 
E-cadherin activates β-catenin signaling and downstream activation of NF-κB [36]. 
Together these studies demonstrate that F. nucleatum is capable of promoting intestinal 
tumorigenesis. F. nucleatum also shows promise as a biomarker for CRC. Using qPCR, 
Kostic et al. detected F. nucleatum in the stool of 27 out of 27 cancer patients with 
carcinomas, 24 of 28 patients with adenomas, and 15 out of 31 healthy individuals. 
Many other studies have observed an enrichment of F. nucleatum in CRC patients 
relative to controls, making it arguably the best single-species biomarker for CRC [37–
40]. 
Multi-species models for detecting CRC 
Attempts to use individual species as biomarkers for CRC have had limited success, as 
none of the strains mentioned above is present in the majority of CRC cases. To 
address this problem, several groups have attempted to use a combination of bacterial 
species to differentiate healthy individuals from those with CRC. Zackular et al. 
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demonstrated that logit models using 5 or 6 bacterial species could detect carcinomas 
just as well as a model using traditional risk factors (age, race, and BMI) and could 
detect adenomas better than those risk factors [40]. They also showed that combining 
bacterial species with patient risk factors and/or gFOBT could improve the detection of 
CRC over any one method by itself. Among the most predictive populations were ones 
associated with Fusobacterium and Porphyromonas. Limitations of this study were that 
it included only 90 patients (30 normal, 30 adenoma, 30 carcinoma) and did not perform 
any validation of the models. 
Shortly thereafter, Zeller et al., with a larger patient cohort, developed a model using the 
relative abundance of 22 bacterial species that could detect CRC better than gFOBT 
[39]. Again, they found that combining a microbiota-based model with gFOBT improved 
detection of CRC over either method alone. Importantly, they validated their model by 
applying it to two external datasets. The bacterial species that were most predictive of 
CRC were Porphyromonas asaccharolytica, Petpostreptococcus stomatis, and two 
strains of F. nucleatum. Also of interest, was the observation that models based on 
metagenomic markers were no better than models based on 16S rRNA gene 
abundances. 
In 2015 Yu et al. developed a model based on 20 microbial gene markers [37]. Genes 
associated with F. nucleatum, Peptostreptococcus stomatis, and Parvimonas micra, 
were among the most predictive biomarkers. Building from these findings, Chapter 3 of 
this dissertation describes microbiota-based models we developed for detecting CRC 
based on the microbiota [41]. We showed that combining bacterial abundances with 
fecal hemoglobin concentrations from FIT could further improve the sensitivity for CRC, 
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especially early stage lesions. Like the aforementioned studies, we found that oral 
species, including F. nucleatum, P. asaccharolytica, P. micra, and P. stomatis, were the 
most overrepresented in CRC samples. 
Combining FIT with other biomarkers is not a new idea. The multitarget stool DNA test 
combines FIT with several other host-associated biomarkers into a model for 
determining whether an individuals has CRC. One barrier to combining microbiota-
based screening with other tests is the need to collect and store an additional stool 
sample for microbiota characterization. Patients who perceive stool collection as 
inconvenient or indelicate may be dissuaded from adhering to screening guidelines. 
Furthermore, stool collection could have added financial costs from collection materials, 
processing, and storage. Thus, an alternative source of material for microbiota analyses 
is needed. 
Sinha et al. compared several sampling methods, including used gFOBT cards and 
rectal swabs. Despite some biases between methods, they found that gFOBT cards 
offered a high level of stability and reproducibility as source of fecal material for 16S 
rRNA gene sequencing [42]. This showed that microbiota analyses and blood detection 
could be carried out from a single convenient sample. However, gFOBT is largely being 
replaced by the more accurate FIT method. Therefore an alternative would be to utilize 
the residual fecal material contained within the FIT sampling cartridges after they have 
been used for hemoglobin quantification. In Chapter 4 of this dissertation, we tested 
whether the residual buffer from FIT cartridges could be used for microbiota 
characterization. We found that, indeed, bacterial DNA isolated from FIT cartridges 
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recapitulated the composition of the fecal microbiota and could be used to identify 
patients with CRC with the same accuracy as DNA isolated directly from stool. 
Regardless of whether the shifts in the microbiota are the cause or effect of 
tumorigenesis, such shifts show potential as biomarkers for CRC. As we continue to 
better understand the role of the microbiota in CRC, we may be able to develop 
improved methods for screening, accelerating the downward trend in CRC incidence 
and mortality. Chapters 2, 3, and 4 of this dissertation advance the field through three 
important findings: 1.) An individual’s baseline microbiota may influence their 
susceptibility to tumorigenesis. 2.) Changes in an individual’s microbiota can be used in 
conjunction with FIT to more accurately detect lesions. 3.) DNA from FIT cartridges are 
an alternative source of material for microbiota-based screening. Chapter 5 will discuss 
the implications of these findings and the future of microbiota-based screening for CRC. 
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CHAPTER 2:  
Structure Of The Gut Microbiome Following Colonization 
With Human Feces Determines Colonic Tumor Burden 
  
The contents of this chapter have been published as: 
Baxter NT*, Zackular JP*, Chen GY, Schloss PD. (2014).  Structure of the gut 
microbiome following colonization with human feces determines colonic tumor burden.  
Microbiome 2(1):20. *Equal Contributon 
 
 
 
Abstract 
A growing body of evidence indicates that the gut microbiome plays a role in the 
development of colorectal cancer (CRC). CRC patients harbor gut microbiomes that are 
structurally distinct from those of healthy individuals; however without the ability to track 
individuals during disease progression, it has not been possible to observe changes in 
the microbiome over the course of tumorigenesis. Mouse models have demonstrated 
that these changes can further promote colonic tumorigenesis. However, these models 
have relied upon mouse-adapted bacterial populations and so it remains unclear which 
human-adapted bacterial populations are responsible for modulating tumorigenesis. We 
transplanted fecal microbiota from three CRC patients and three healthy individuals into 
germ-free mice, resulting in six structurally distinct microbial communities. Subjecting 
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these mice to a chemically induced model of CRC resulted in different levels of 
tumorigenesis between mice. Differences in the number of tumors were strongly 
associated with the baseline microbiome structure in mice, but not with the cancer-
status of the human donors. Partitioning of baseline communities into enterotypes by 
Dirichlet multinomial mixture modeling resulted in 3 enterotypes that corresponded with 
tumor burden. The taxa most strongly positively correlated with increased tumor burden 
were members of the Bacteroides, Parabacteroides, Alistipes, and Akkermansia, all of 
which are Gram-negative. Members of the Gram-positive Clostridiales, including 
multiple members of Clostridium Group XIVa were strongly negatively correlated with 
tumors. Analysis of the inferred metagenome of each community revealed a negative 
correlation between tumor counts and the potential for butyrate production, and a 
positive correlation between tumor counts and the capacity for host glycan degradation. 
Despite harboring distinct gut communities, all mice underwent conserved structural 
changes over the course of the model. The extent of these changes was also correlated 
with tumor incidence. Our results suggest that the initial structure of the microbiome 
determines the susceptibility to colonic tumorigenesis. There appear to be opposing 
roles for certain Gram-negative (Bacteroidales and Verrucomicrobia) and Gram-positive 
(Clostridiales) bacteria in tumor susceptibility. Thus, the impact of community structure 
is potentially mediated by the balance between protective, butyrate producing 
populations and inflammatory, mucin degrading populations. 
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Background 
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the 
United States each year [1]. Recent evidence suggests that the community of microbes 
inhabiting the gastrointestinal tract plays an important role in the development and 
progression of CRC [2-4]. This community, termed the gut microbiome, is known to 
influence cancer-related functions including cell proliferation, angiogenesis, and 
apoptosis, and it is strongly linked to diet, obesity and inflammation, which are known 
risk factors of CRC [5-9]. Using a mouse model of CRC, we have shown that structural 
changes to the microbiome occur during tumorigenesis and result in a gut microbiome 
with an increased tumorigenic capacity [10]. These findings demonstrate that the gut 
microbiome has a causal role in the development and progression of CRC. 
 
Several survey-based studies have shown that CRC patients harbor microbial 
communities that are structurally distinct from those of healthy individuals [11-15]. 
However, there has been no consensus among these studies as to which bacterial 
populations are important. In mouse models several gut commensals have been shown 
to promote tumorigenesis in the colon. Both enterotoxigenic Bacteroides fragilis (ETBF) 
and strains of Escherichia coli that carry the pks pathogenicity island can promote 
tumorigenesis by the production of toxins [3, 4].  Fusobacterium nucleatum has also 
been shown to potentiate tumorigenesis in mouse models and cell culture experiments 
by stimulating inflammation via myeloid cell recruitment and/or activation of β-catenin 
signaling [2, 16]. Fusobacterium was also found to be enriched in a subset of human 
colon adenomas [15]. Although there is increasing evidence that Fusobacterium is 
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involved in CRC cases, it was detected in less than half of adenomas, which suggests 
that other bacterial populations are capable of potentiating tumorigenesis [2]. In fact, it 
may be that CRC is a polymicrobial disease requiring combinations of these or other 
populations to influence tumorigenesis. 
 
While individual bacterial species have been associated with some human CRC cases, 
in other cases the capacity of the microbiome to modulate tumorigenesis could be 
determined by the structure of the community as a whole rather than the presence or 
absence of individual populations [4, 17]. The potentially polymicrobial influence of the 
gut microbiome on this disease necessitates the disentangling of the complex 
interactions between bacterial populations in the gut. Understanding these interactions 
requires investigation of the relationship between the microbiome and tumorigenesis 
under a diverse set of community structures. Unfortunately, mechanistic studies 
typically rely on experiments with conventionally reared inbred mouse living in 
homogenous, controlled environments, leading to relatively little variation in microbiome 
structure between individual animals. Although, experiments in conventional mice are 
useful for understanding the mechanisms by which the microbiome modulates 
tumorigenesis, they are limited by investigating only those bacterial strains found in 
laboratory mice, many of which are absent in humans. It is reasonable to expect that 
incorporating human-associated microbial populations into these experiments would 
increase the ability to translate results to humans. 
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To investigate the role of microbiome structure in tumorigenesis, we combined the 
advantages of the high interpersonal variation among humans and the convenience of a 
mouse model. We inoculated germ-free mice with microbiota from human subjects 
harboring distinct microbiomes. This technique enabled us to test the effect of different 
baseline microbiome communities with variation beyond what is seen in conventionally 
reared mice. The transfer of human microbiota to germ-free mice, sometimes referred to 
as “humanization”, has been employed to study the microbiome in the context of several 
other diseases. In studies of diabetes, obesity, and malnutrition, colonization with 
human feces has been reported to recapitulate the phenotype of the human donors in 
the recipient mice [18-21]. Thus, in addition to searching for tumor-modulating 
community structures, we sought to determine whether this strategy could be used to 
recapitulate the tumor-promoting capacity of CRC patients’ microbiota in mice. 
 
 
Methods 
Mouse experiments 
Fecal samples from three healthy individuals and three patients found to harbor 
carcinomas were obtained through the Early Detection Research Network (Table 2.1). 
Diagnoses were determined based on colonoscopy and histology.  All six samples were 
PCR-negative for the ETBF toxin and  the E. coli pks island [4, 22].  Inocula were 
prepared by mixing 200 mg of each sample in 5ml of PBS. Age-matched (6-10 weeks), 
male, germ-free C57BL/6 mice were inoculated by oral gavage with 100 µl of inoculum 
(n=10 for groups H1 and C1, n=5 for others). Mice were housed 5 mice per cage. Three 
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weeks after inoculation mice received a single intra-peritoneal injection of 
azoxymethane (AOM) (10 mg/kg of body weight). Five days later mice were subjected 
to the first of three five-day rounds of 2% dextran sulfate sodium (DSS) administered ad 
libitum in the drinking water (Figure 2.1). Sixteen days of recovery separated each 
round of DSS. Three weeks after the third and final round of DSS mice were euthanized 
and colonic tumors were enumerated. With this model mice consistently develop 
noninvasive adenomas with dysplastic changes [23, 24]. Throughout the experiment the 
mice were housed in germ-free isolators at the University of Michigan Germ-free 
Facility. This animal experiment was approved by the University Committee on Use and 
Care of Animals at the University of Michigan. 
 
DNA extraction and 16S rRNA gene sequencing 
Mouse fecal samples were collected throughout the experiment and frozen at -20˚C. 
Genomic DNA from samples collected on days 0 and 73 and the human inocular were 
isolated using the PowerSoil-htp 96 Well Soil DNA isolation kit (Mo Bio) using an 
EpMotion 5075 automated pipetting system. The V4 region of the 16S rRNA gene was 
amplified using custom barcoded primers and sequenced as described previously using 
an Illumina MiSeq sequencer [25]. All fastq files and the MIMARKS spreadsheet are 
available at http://www.mothur.org/human_mouse_aomdss. 
 
Sequence curation and analysis 
16S rRNA gene sequences were curated using the mothur software package as 
described previously [25, 26]. Briefly, paired end reads were assembled into contigs and 
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aligned to the SILVA 16S rRNA sequence database [27]. Sequences that failed to align 
or were flagged as possible chimeras by UCHIME were removed [28]. Each sequence 
was classified using a Naïve Bayesian classifier trained against a 16S rRNA gene 
training set provided by the Ribosomal Database Project (http: 
//sourceforge.net/projects/rdp-classifier/) [29]. Finally, sequences were grouped based 
on their taxonomic classification or clustered into operational taxonomic units (OTUs) 
based on a 97% similarity cutoff. The number of sequences in each sample was 
rarefied to 3,306 sequences per sample to minimize the effects of uneven sampling. 
Parallel sequencing and processing of a mock community indicated that the error rate of 
the curated sequences was 0.085%. 
 
The dissimilarity in community structure between samples was calculated using the ΘYC 
metric [30]. The ΘYC distances between samples were used for ordination analysis by 
non-metric dimensional scaling (NMDS) in two dimensions. Ten iterations were 
performed and the resulting ordination that had the lowest stress was used for data 
visualizations. Dirichlet multinomial mixture models were generated to group samples 
into enterotypes based on the abundance of bacterial genera in each sample [31]. To 
identify conserved changes that occurred over the course of the AOM/DSS model, the 
samples from each mouse on day 0, and the samples collected at the end of the model 
were grouped into “baseline” and “endpoint” categories respectively. The R 
randomForest package was used to identify the OTUs that best distinguished between 
the two categories based on their importance for the classification model [32, 33]. 
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The Phylogenetic Investigation of Communities by Reconstruction of Unobserved 
States (PICRUSt) software package was used to infer the metagenomic content of each 
sample, based on the taxonomy and abundance of each OTU [34]. Although this 
method is limited by the number of available genomes, it has been shown to replicate 
metagenomes to a high degree of accuracy, especially for human-adapted bacterial 
communities. The weighted Nearest Sequenced Taxon Index (NSTI) for our samples 
was 0.056 +/- 0.01. In general, NSTI values below 0.06, suggest that closely related 
reference genomes were available the dataset 
(http://picrust.github.io/picrust/tutorials/quality_control.html). From the inferred 
metagenomes, we identified KEGG orthologs that could be used as markers for 
butyrate production or host-glycan degradation. Because either butyrate kinase or 
butyryl CoA:acetate CoA transferase is required for butyrate production in the gut, the 
KEGG orthologs chosen as markers for butyrate production were K00929 (butyrate 
kinase [EC:2.7.2.7]), K01034 (acetate CoA-transferase alpha subunit [EC:2.8.3.8]), 
K01035 (acetate CoA-transferase beta subunit [EC:2.8.3.8]) [35]. To choose markers 
for glycan degradation, we found all of the KEGG orthologs annotated as sialidases, 
fucosidases, sulfatases, or members of the glycoside hydrolase family 18, as these 
classes of enzymes are necessary, and moderately specific for host glycan degradation 
[36, 37]. Ten such KEGG orthologs were found in the metagenomes, and used as 
markers;  K01138 (uncharacterized sulfatase [EC:3.1.6.-]), K01130 (arylsufatase 
[EC:3.1.6.1]), K01135 (arylsufatase B [EC:3.1.6.12]), K01137 (N-acetylglucosamine-6-
sulfatases [EC:3.1.6.14]), K01134 (arylsufatase A [EC:3.1.6.8]), K01186 (sialidase-1 
[EC:3.2.1.18]), K01206 (alpha-L-fucosidase [EC:3.2.151]), K01183 (1,4-beta-poly-N-
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acetylglucosaminidase [EC:3.2.1.14]), K01205 (alpha-N-acetylglucosaminidase 
[EC:3.2.1.50]), and K05970 (sialate O-acetylesterase [EC:3.1.1.53]). Finally, we 
calculated the Spearman correlation coefficients between tumor counts and these 
KEGG orthologs. 
 
Statistical Analyses 
Differences in tumor counts between DMM partitions were examined using a Wilcoxon 
rank-sum test. To test whether there was a significant difference in tumor counts 
between groups that received healthy or cancer-associated inocula, we rank 
transformed the tumor counts to correct for heteroscedasticity and performed a nested 
ANOVA.  Differences in community structure were examined using Analysis of 
Molecular Variance (AMOVA) in mothur. 
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Figure 2.1. Experimental Design. Germ-free mice were inoculated by oral gavage with 
one of six human inocula. Twenty-one days later (day 0) they received a single intra-
peritoneal injection of AOM (10 mg/kg). Mice were subsequently administered three 
five-day rounds of 2% DSS in the drinking water, with sixteen days of rest in between. 
Mice were euthanized seventy-three days after the AOM injection for enumeration of 
colonic tumors. The inocula and samples collected on day 0 and day 73 were used for 
16S rRNA sequencing. 
 
 
 
Table 2.1. Metadata for the six inoculum donors. 
−20 −10 0 10 20 30 40 50 60 70
Day
Inoculation AOM
DSS1 DSS2 DSS3
Necropsy
Patient Age)) Gender Race
Height)
(cm)
weight)
(kg)
FOBT)
result Medications Diagnosis Stage) Location
Min)tumor)
size(cm)
Max)tumor)
size))(cm)
C1 74%% f%% white 157 79 . Exelon,%Furosemide,Trazodone Cancer IIIc%% rectal 9.5 9.5
C2 63%% m%% asian 167 86 + nexium,%metformin Cancer I%% rectal% 1.2 2.1
C3 60%% m%% white 182 109 + Claritan Cancer IIIb%% rectal 2 3.1
H1 52%% f%% white 162 84 . requip Normal n/a n/a n/a n/a
H2 69%% f%% white 157 46 . none Normal n/a n/a n/a n/a
H3 55%% f%% asian 157 73 . cyclobenzaprine%HCL Normal n/a n/a n/a n/a
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Results 
Colonization of germ-free mice with human microbiota 
We colonized germ-free mice with human feces from six individuals to determine 
whether different initial community structures would yield different numbers of tumors 
after going through the AOM/DSS model. Three of the donors had healthy colons (H1, 
H2, H3) and three had colonic carcinomas (C1, C2, C3). Samples were chosen 
because they represented broad variation in community structure (Figure 2.2A). 
Following gavage and a 21-day colonization period, groups showed varying levels of 
similarity to their inocula based on phylum level relative abundances and the Θ YC 
distances calculated from OTU abundances (Figure 2.2B). Low Θ YC distances between 
mice within groups suggested that individual communities were consistent within each 
group, while large ΘYC distances between groups suggest that each group harbored a 
gut microbiome that was structurally distinct from the others. Pairwise AMOVA between 
groups revealed that colonization with different inocula resulted in significantly different 
community structures (p<0.01, Benjamini-Hochberg correction). These results suggest 
that although mice do not closely resemble their inoculum, all sets of mice developed 
stable, structurally distinct communities. 
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Figure 2.2. Taxonomic composition and beta diversity across treatment groups 
and time. (A) Phylum level relative abundance of the fecal microbiome of each group 
and in its inoculum. (B) Average ΘYC distances(+/- SEM) within and between groups at 
various time points; between each group and its inoculum, within each group at day 0, 
each group compared to others at day 0, between day 0 and day 73 for each group, and 
each group compared to others at day 73.  
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Figure 2.3.  Temporal changes in community structure.  NMDS ordination based 
OTU abundances between samples on day 0 and day 73.  Distances were calculated 
with ΘYC.  
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Tumor incidence is linked to initial community structure 
Once colonized, mice were subjected to the AOM/DSS model of CRC. We observed 
significant variation in the number of tumors between mice (Figure 2.4A). These 
differences were associated with the inoculum they received, but not the cancer status 
of the human donor (Nested ANOVA p<0.0005). Thus the phenotype of the human 
subject was not transferred to their mouse counterparts. Ordination of the communities 
revealed an association between the community structure of each group at the 
beginning of the AOM/DSS model and their median tumor counts (Figure 2.4B).  To test 
for cage effects groups H1 and C1 were each inoculated into duplicate cages of 5 mice 
each (n=10 per inoculum).  There was no significant difference in microbiome structure 
(p>0.05, AMOVA) or tumor counts (p>0.05, Wilcoxon test) between cages within each 
group. 
 
To determine which OTUs were driving this trend, we generated a biplot using the 
NMDS axes generated from the Θ YC distances between samples collected at the time 
of AOM injection (day 0) (Figure 2.4B). Among the OTUs most strongly correlated with 
high tumor counts were two OTUs from the genus Bacteroides (OTUs 1 and OTU 4). 
More detailed characterization of these OTUs indicated that OTU 1 was closely affiliated 
with B. uniformis and OTU 4 was affiliated with a mixture of a mixture of Bacteroides 
spp. including B. fragilis, B. ovatus, B. xylanisolvens and B. thetaiotaomicron. Both of 
these OTUs were found in all six cohorts of mice and their initial abundances were 
positively correlated with tumor counts (ρ=0.47 and 0.49, respectively; both p<0.005; 
Spearman correlation). Interestingly, all samples were PCR-negative for the ETBF toxin 
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gene, suggesting that OTU 4 was not ETBF. Other OTUs associated with high tumor 
counts were affiliated with the genera Parabacteroides (OTU 18), Alistipes (OTU 19), 
and Bacteroides as well as an OTU affiliated with the species Akkermansia muciniphila 
(OTU 11). In addition, several OTUs associated with the Clostridium Group XIVa (OTUs 
7, 9, 15, and 17), Clostridium Group IV (OTU 49), and unclassified members of the 
Lachnospiraceae (OTUs 67 and 13) were correlated with lower tumor counts. These 
results indicate that the relative abundance of specific OTUs in the starting community 
could be associated with tumor counts. 
	 32	
 
Figure 2.4. Correlation of tumor incidence with initial gut community structure. 
(A) Stripchart of tumor counts (with line at median) for each group. (B) NMDS plot 
based on ΘYC distances between samples at day 0 with biplot of the 15 OTUs most 
strongly correlated with the NMDS axes (stress = 0.21). Median tumor counts for each 
group are adjacent to their corresponding dots. 
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To further test the association between the starting community structure and tumor 
incidence we clustered samples into community types using Dirichlet multinomial 
mixture (DMM) models based on the abundance of bacterial genera found in the mice. 
This approach allowed us to quantify the association between the starting community 
structure and tumor burden in an unbiased manner. The DMM model with the highest 
likelihood partitioned the samples into three enterotypes (Figure 2.5A). Enterotype 1 
was composed exclusively of samples from the three treatment groups with the highest 
tumor counts (H2, C3, H1). Enterotype 2 was composed of samples from C1, which had 
the third lowest tumor counts. Enterotype 3 was composed entirely of samples from the 
two groups with the lowest tumor counts (C2, H3). As a result, mice in Enterotype 1 had 
significantly more tumors than the other two partitions (p<0.05, Wilcoxon test; Figure 
2.5B). Consistent with the OTU analysis, the DMM partition with the highest tumor 
counts was enriched for the genus Bacteroides (Figure 2.5C). In addition, other genera 
within the order Bacteroidales (Parabacteroides and Alistipes), as well as Akkermansia 
were enriched in Enterotype 1. An unclassified member of the Porphrymonodaceae, 
was enriched in Enterotype 2, which had significantly fewer tumors than Enterotype 1. 
Enterotype 3, which had the fewest tumors, was enriched for several genera within the 
order Clostridiales (Clostridim Group XIVa, Clostridium Group XI, Clostridium Group 
XVIII, Flavonifractor, and unclassified Lachnospiraceae). These data suggest a 
potentially tumorigenic role for certain members of Bacteroidales and a protective role 
for certain members of Clostridiales. 
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Figure 2.5. Correlation of enterotypes with tumor incidence. (A) NMDS plot based 
on genus level abundances with median tumor counts for each group (stress = 0.13) . 
Samples are circled based on their DMM enterotype. (B) Tumor counts for the mice in 
each DMM enterotype (* p<0.05, **p<0.01, Wilcoxon rank-sum test)  (C) Relative 
abundance of the genera with the largest differences between enterotypes. 
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Changes in the microbiome during the AOM/DSS model 
To determine the extent to which the microbiomes of each group changed over the 
course of the AOM/DSS model we calculated the ΘYC distances between the 
communities in mice at the time of AOM injection and at the end of the experiment. 
Interestingly, the two groups with the highest tumor counts (H2, C3) changed very little 
over time (ΘYC=0.12 and 0.14), while the microbiomes of the three groups with the 
lowest tumor counts (C2, H3, C1) changed substantially (ΘYC = 0.73, 0.76, 0.83) (Figure 
2.2A). Thus the closer the initial community of each group was to the tumor-associated 
endpoint community, the more tumors those mice developed. 
 
To identify which OTUs changed over time, we combined samples from all six treatment 
groups and used the Random Forest machine-learning algorithm to identify the OTUs 
that allowed us to differentiate between the samples from the beginning and end of the 
model, regardless of the inoculum. The resulting model was able to distinguish between 
the baseline and endpoint samples with 98.6% accuracy. The OTUs that provided the 
greatest mean decrease in accuracy when removed from the analysis were affiliated 
with Turicibacter (OTU 36), Bacteroides (OTU 4), Porphyromonadaceae (OTU 59), and 
several genera within the Clostridiales (OTUs 113, 25, 28, 127, 144, 42, and 17; Figure 
2.6).  Despite harboring drastically different community structures, all treatment groups 
underwent conserved changes in microbiome structure over the course of the model. 
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Figure 2.6. Temporal changes in the microbiome are conserved between groups. 
Strip chart showing the relative abundances of the 10 OTUs with the highest importance 
for distinguishing between baseline (day 0) and endpoint (day 73) communities by 
random forest as measured by the mean decrease accuracy (MDA) when the OTU was 
removed from the model.  Each dot represents a single mouse.  The black lines 
represent the mean relative abundance for all mice.   
Relative Abundance (%)
● ●
●
●● ●
●● ●
●● ●
● ●
●
●
●●
●● ●●
●
● ●●
●
●
● ●●
● ●
● ●
●
●
●
●
●● ●
●●●
●
●
● ●●
●
●●
●
●●
●●●
●
●
●
●●
●
●●
●
● ●●
●
●●● ●
●
●
●
● ●●
● ●
●●●
● ●
●●
● ●
● ●
●
●
●●
●
● ●●
●
●●●
●● ●●
●
●
●
●●
●● ●
●
● ●●
●● ●● ●
●
●
●
●
●●
●● ●
●
● ●● ●● ●●●
●●● ●●
●
●
●
●
●●
●
●● ●●
●
●
●●●
● ● ●
●
●
●
●
● ●
●
●
●● ●
●
●
●
●●●
●● ●●
●
●
●
●
●
●
●
●
●
● ●
● ●
●
●
●
●
● ●● ●
● ●●
●
●
● ●●●●
●
● ● ●●
●●
●
●
●
●
●
● ●●
●
●●●
●●
● ●
●
●
●
●● ●
● ●
●
●
●●●
● ●
●
●
●
● ●
● ●
●
● ●●
●
●
●
●●
●●● ●
●
●
● ● ●
●●●
●● ●● ●
● ●
● ●
●
●
●
● ●
●
●● ●
●●
●
●
●
● ● ● ●●
●
●
●
●
●
● ●
●●
●
● ●
●●●●
●
●
●● ●●
● ●
●●
●
●● ● ●
●
●
●
●●
Clostridium XIVa
(OTU 17; MDA=50.3)
Porphyromonodaceae
(OTU 59; MDA=50.8)
Blautia
(OTU 42; MDA=51.3)
Lachnospiraceae
(OTU 144; MDA=58.7)
Lachnospiraceae
(OTU 127; MDA=59.4)
Clostridium XVIII
(OTU 28; MDA=69.2)
Blautia
(OTU 25; MDA=74.5)
Ruminococcus
(OTU 113; MDA=83.0)
Bacteroides
(OTU 4; MDA=86.3)
Turicibacter
(OTU 36; MDA=91.8)
0 0.1 1 10 100
●
●
Baseline
Endpoint
	 37	
 
Figure 2.7. Samples remain in same enterotypes over the course of the model.  
NMDS ordination showing DMM enterotypes generated based on genus level 
abundances on day 73.  Distances were calculated with ΘYC.  Despite changes in OTU 
abundance over the course of the model, all mice cluster into the same enterotypes on 
day 73 as they did on day 0.   
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Tumor incidence is linked to butyrate production and host glycan degradation. 
Our experiments suggested that Clostridiales, Bacteroidales and Akkermansia played a 
role in modulating tumorigenesis. Members of the Clostridiales, especially Clostridium 
Group XIVa, are the predominate producers of intestinal butyrate, an important anti-
inflammatory and anti-tumorigenic metabolite in the gut [35, 38, 39] Bacteroides and 
Akkermansia, on the other hand, are known to breakdown host-derived glycans, 
especially mucin. Mucin degradation has been linked to intestinal inflammation and can 
facilitate colonization of intestinal pathogens [40-42]. To test whether the genomic 
potential for these metabolic activities is linked to tumor incidence, we used the 
PICRUSt software package to predict the metagenomic content for each sample at the 
time of AOM injection. Butyrate production in the gut requires either butyryl-
CoA:acetate-CoA transferase or butyrate kinase [30]. KEGG Orthologs (KOs) of the 
alpha and beta subunits of butyryl-CoA:acetate-CoA transferase were negatively 
correlated with tumor incidence (r<-0.35, p<0.05,). Butyrate kinase had the same trend, 
but the correlation was not statistically significant (r=-0.30, p=0.08). Next, we identified 
KOs for sialidases, fucosidases, sulfatases, and N-acetylglucosaminidases, which are 
indicative of host glycan degradation [36, 37]. Of the 10 such KOs found in our 
metagenomes, 7 (two arylsulfatases, an uncharacterized sulfatase, alpha-L-fucosidase, 
sialate O-acetylesterase, alpha-N-acetylglucosaminidase, 1,4-beta-poly-N-
acetylglucosaminidase) were positively correlated with tumor count (r>0.47, p <0.01). 
None of the 3 remaining KOs were correlated with tumors. Together, these data 
suggest that the correlation between tumor incidence and the microbiome may be 
dependent on metabolic activity rather than bacterial phylogeny. 
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Discussion 
The results of this study demonstrate that the structure of the gut microbiome is 
important for determining susceptibility to inflammation-associated tumorigenesis. We 
observed strong correlations between initial community structure of the gut microbiome 
and tumor multiplicity. This relationship is driven primarily by two distinct groups of 
bacteria. In general we found that members of the Bacteroidales (Bacteroides, 
Parabacteroides, Alistipes, and Porphrymonodaceae) were associated with a higher 
rate of tumorigenesis, while members of the Clostridiales, especially Clostridium Group 
XIVa, were associated with a decreased rate of tumorigenesis. There were exceptions 
to this pattern however, as a few OTUs associated with Clostridiales (OTUs associated 
with Roseburia, Blautia, and Subdoligranulum) were enriched in the groups with higher 
tumor counts (Figure 2.4B). However, these OTUs were less abundant (<0.7% mean 
abundance) than those Clostridales that were negatively correlated with tumors (~2% 
mean abundance). Therefore the data generally support a model in which susceptibility 
to colonic tumorigenesis is determined by the balance between the abundance of 
members of Bacteroidales and Clostridiales.  One limitation of this study is that we only 
assayed the fecal communities. While this was necessary for correlating baseline 
community structure with the numbers of tumors that developed, characterization of the 
mucosal microbiota could potentially yield additional associations with tumor burden. It 
is also important to note that, although we observed variation in the number of tumors 
within inoculum groups, we were unable to correlated these differences with any 
differences in their microbiomes. 
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Based on our predicted metagenomic analysis, the roles of Clostridiales and 
Bacteroidales could be dependent on specific metabolic activities. Members of 
Clostridium Group XIVa are the predominant producers of butyrate in the gut [35]. Given 
the anti-inflammatory and anti-tumorigenic properties of intestinal butyrate, its 
production by members of Clostridium Group XIVa could explain the association with 
lower susceptibility to colon tumorigenesis [38, 39]. This hypothesis is supported by our 
predicted metagenomic data, which correlated the increased potential for butyrate 
production with decreased tumorigenesis. Bacteroides and Akkermansia were the two 
genera most strongly correlated with higher rates of tumorigenesis. Both are known 
mucin degraders, and several genes linked to mucin degradation were positively 
correlated with tumor incidence. Additionally, previous studies have linked mucin 
degradation by Bacteroides and Akkermansia with intestinal inflammation [40-42]. It is 
possible that an overabundance of these or other mucin degraders could undermine the 
integrity of the mucosal barrier, leading to increased inflammation. Such a mechanism 
could be an alternative to the ETBF-based model of tumorigenesis as we were unable 
to detect the gene for the ETBF toxin in any of our samples. While we cannot exclude 
the possibility of a novel toxin in the Bacteroides populations in our experiment, the 
additional correlation with Akkermansia muciniphila supports a model in which 
inflammation is induced by mucin degradation. If further experiments confirm this model, 
blocking mucin degradation could be a used as a therapeutic for preventing or slowing 
the progression of tumorigenesis.  
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In this study we observed a relationship between tumor multiplicity and the extent to 
which the microbiome shifted over the course of the model. The gut community of mice 
with high tumor counts changed very little over the course of the model, while the 
microbiome of groups with low tumor counts changed drastically. Thus the more similar 
the baseline community was to the endpoint community, the more tumors the host 
developed. We hypothesize that the microbiome of these mice was not significantly 
altered by the AOM/DSS model since it was already in a state of dysbiosis. Therefore, 
there was a greater exposure to a tumorigenic microbiome. Similarly, in a previous 
study we colonized germ-free mice with the feces of conventional mice that had already 
gone through the model [10]. These mice developed more tumors than germ-free mice 
colonized with feces from normal mice. Thus, in addition to needing a dysbiotic 
community to exacerbate tumorigenesis, the length of exposure to that community is 
important to tumor formation. 
 
In contrast to earlier studies where human feces were used to colonize germ-free mice, 
we were unable to recapitulate the structures of the human microbiota donors, as 
numerous members of the donor community failed to colonize the recipients and others 
colonized in different abundances. For example, one of the donor communities (C1) 
was dominated by Fusobacterium spp (58% relative abundance).  Another inoculum 
(C3), contained F. nucleatum at 2% relative abundance [2]. However we did not recover 
any sequences from the Fusobacteria phylum in the recipient mice. We were also 
unable to culture it from the original human stool sample, suggesting it may not have 
survived the freezing and thawing of the sample or was never alive in the stool. While 
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we did not fully recapitulate the community structure or phenotype of the human donors, 
colonizing mice with human fecal communities did serve as a useful tool for generating 
novel community structures to test the influence of specific bacterial populations on 
tumorigenesis. This strategy also allowed us to investigate the role of human 
microbiota, which should be more clinically relevant, while maintaining the tractability of 
a mouse model. 
 
 
Conclusions 
In this study we found that the process of colonizing germ-free mice with human fecal 
communities did not recapitulate the phenotype of the human donors in this particular 
mouse model of CRC. Nonetheless, our findings demonstrate the importance of the 
initial microbiome structure in determining the rate of tumorigenesis. Furthermore, we 
identified several bacterial populations correlated with tumor incidence in the context of 
six distinct gut communities. Multiple OTUs associated with the order Bacteroidales and 
the species Akkermansia muciniphila were correlated with exacerbated tumorigenesis, 
while several OTUs associated with Clostridium Group XIVa and other Clostridiales 
were correlated with protection. Based on inferred metagenomes of the baseline 
communities, we provided evidence that the positive correlations between Akkermansia 
and Bacteroidales and tumor incidence could be a result of their ability to degrade 
mucin, and the negative correlation between the Clostridiales and tumor incidence could 
be due to the production of butyrate. The results are consistent with a model in which 
susceptibility is determined by the balance between mucin degradation and short chain 
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fatty acid production. More studies are needed to confirm theses results and to test the 
mechanisms by which these or other bacterial populations influence colon 
tumorigenesis. A better understanding of microbiome structures with a propensity to 
promote or inhibit tumorigenesis could lead to the development of prebiotic or probiotic 
therapies to prevent or slow the development and progression of CRC. 
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CHAPTER 3:  
Microbiota-based model improves the sensitivity of fecal 
immunochemical test for detecting colonic lesions 
 
The contents of this chapter have been published as: 
Baxter NT, Ruffin MT IV, Rogers MAM, Schloss PD. (2016).  Microbiota-based model 
improves the sensitivity of fecal immunochemical test for detecting colonic lesions.  
Genome Medicine 8(1):37. 
 
Abstract 
Colorectal cancer is the second leading cause of death among cancers in the United 
States. Although individuals diagnosed early have a greater than 90% chance of 
survival, more than one-third of individuals do not adhere to screening 
recommendations partly because the standard diagnostics, colonoscopy and 
sigmoidoscopy, are expensive and invasive. Thus, there is a great need to improve the 
sensitivity of non-invasive tests to detect early stage cancers and adenomas. Numerous 
studies have identified shifts in the composition of the gut microbiota associated with the 
progression of colorectal cancer, suggesting that the gut microbiota may represent a 
reservoir of biomarkers that would complement existing non-invasive methods such as 
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the widely used fecal immunochemical test (FIT). We sequenced the 16S rRNA genes 
from the stool samples of 490 patients. We used the relative abundances of the 
bacterial populations within each sample to develop a random forest classification 
model that detects colonic lesions using the relative abundance of gut microbiota and 
the concentration of hemoglobin in stool. The microbiota-based random forest model 
detected 91.7% of cancers and 45.5% of adenomas while FIT alone detected 75.0% 
and 15.7%, respectively. Of the colonic lesions missed by FIT, the model detected 
70.0% of cancers and 37.7% of adenomas. We confirmed known associations of 
Porphyromonas assaccharolytica, Peptostreptococcus stomatis, Parvimonas micra, and 
Fusobacterium nucleatum with CRC. Yet, we found that the loss of potentially beneficial 
organisms, such as members of the Lachnospiraceae, was more predictive for 
identifying patients with adenomas when used in combination with FIT. These findings 
demonstrate the potential for microbiota analysis to complement existing screening 
methods to improve detection of colonic lesions. 
Background 
Colorectal cancer mortality has steadily declined in recent decades, due in large part to 
increased screening [1]. Yet current screening tests, the fecal immunochemical test 
(FIT) and the multitarget DNA test, have a sensitivity of 7.6% and 17.2%, respectively, 
for detecting non-advanced adenoma – just the type of early lesion that screening is 
meant to identify [2]. Although structural exams including colonoscopy and 
sigmoidoscopy are able to detect both adenomas and carcinomas, the high cost and 
invasive nature are barriers for many people. Fear, discomfort, and embarrassment are 
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among the most cited reasons patients choose to forego CRC screening [3]. Likewise 
the large disparity in screening rates between those with and without health insurance 
highlights the need for inexpensive screening methods [1, 4, 5]. Unfortunately cheaper, 
less invasive stool-based tests like guaic fecal occult blood test and FIT are unable to 
reliably detect adenomas [6]. The newly introduced stool DNA panel has improved 
accuracy compared to FIT, but is still limited in its ability to accurately detect adenomas 
[2]. Thus there is need for novel screening methods that are inexpensive and capable of 
detecting both cancer and adenomas. 
The gut microbiota, the collection of microorganisms that inhabit the gastrointestinal 
tract, are one potential source of biomarkers for detecting colonic lesions. Numerous 
studies have observed alterations in the gut bacterial communities of patients with CRC 
[7–12]. Experiments in animal models have demonstrated that such alterations have the 
potential to accelerate tumorigenesis [13]. Furthermore, several members of the gut 
microbiota have been shown to potentiate both the development and progression of 
CRC by a variety of mechanisms [14–16]. Although each of these organisms may play a 
role in certain cases of CRC, none of them is present in every case. Therefore we 
postulate that no one organism is an effective biomarker on its own and that focusing on 
a single bacterial population excludes the potential that the microbial etiology of the 
disease is actually polymicrobial. 
Two recent studies used statistical models that take into account the abundances of 
multiple bacterial species and the results of guaic fecal occult blood test (gFOBT) to 
distinguish healthy individuals from those with CRC [17, 18]. The analysis by Zackular 
et al. [17] used samples from a limited number of subjects (N=30 normal, 30 adenoma, 
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and 30 carcinoma), while that of Zeller et al [18] had a larger cohort from multiple 
clinical sites (N=156 and N=335). A shortcoming of the Zeller study was the pooling of 
subjects with non-advanced adenomas with control subjects as well as the exclusion of 
subjects with advanced adenomas. A limitation of both studies was that they relied on 
gFOBT rather than FIT to detect hemoglobin in stool. FIT provides a quantitatve 
measure of hemoglobin concentrations and has largely replaced gFOBT clinically 
because of its improved sensitivity. Regardless of their weaknesses, these studies 
demonstrated the feasibility of using microbiome data identify subjects with colonic 
lesions. 
In the present study, we demonstrate the potential for microbiota analysis to 
complement FIT for improved detection of colonic lesions, especially adenomas. We 
utilized the random forest algorithm, which is a decision tree-based machine learning 
algorithm for classification that accounts for non-linear data and interactions among 
features and includes an internal cross-validation to prevent overfitting [19]. With this 
method we identified bacterial populations that could distinguish healthy individuals from 
those with adenomas or carcinomas. In doing so, we confirmed previously observed 
associations of certain bacterial taxa with CRC. Many lesions detected using the 
microbiota were distinct from those detected by FIT, suggesting the microbiota could 
complement FIT to improve sensitivity. By incorporating data on hemoglobin and 
bacterial abundances into a single model (labeled the Multitarget Microbiota Test or 
MMT), we were able to improve the sensitivity for adenomas and cancer compared to 
FIT alone. 
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Methods 
Study Design/Patient sampling. Eligible patients for this study were at least 18 years 
old, willing to sign informed consent, able to tolerate removal of 58 mL of blood, and 
willing to collect a stool sample. Patient age at the time of enrollment ranged from 29 to 
89 with a median of 60. All patients were asymptomatic and were excluded if they had 
undergone surgery, radiation, or chemotherapy for current CRC prior to baseline 
samples or had inflammatory bowel disease, known hereditary non-polyposis CRC, or 
familial adenomatous polyposis. Colonoscopies were performed and fecal samples 
were collected from subjects in 4 locations: Toronto (Ontario, Canada), Boston 
(Massachusetts, USA), Houston (Texas, USA), and Ann Arbor (Michigan, USA). Patient 
diagnoses were determined by colonoscopic examination and histopathological review 
of any biopsies taken. Patients with an adenoma greater than 1cm, more than three 
adenomas of any size, or an adenoma with villous histology were classified as 
advanced adenoma. Whole evacuated stool was collected from each patient either prior 
to colonoscopy preparation or 1-2 weeks after colonoscopy. This has been shown to be 
sufficient time for the microbiota to recover from colonoscopy preparation [20]. Stool 
samples were packed in ice, shipped to a processing center via next day delivery and 
stored at -80˚C. The University of Michigan Institutional Review Board approved this 
study, and all subjects provided informed consent. This study conformed to the 
guidelines of the Helsinki Declaration. 
Fecal Immunochemical Tests. Fecal material for FIT was collected from frozen stool 
aliquots using OC FIT-CHEK sampling bottles (Polymedco Inc.) and processed using an 
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OC-Auto Micro 80 automated system (Polymedco Inc.). Hemoglobin concentrations 
were used for generating ROC curves for FIT and for building the MMT. 
16S rRNA Gene Sequencing. DNA was extracted from approximately 50 mg of fecal 
material from each subject using the PowerSoil-htp 96 Well Soil DNA isolation kit (MO 
BIO Laboratories) and an epMotion 5075 automated pipetting system (Eppendorf). The 
V4 region of the bacterial 16S rRNA gene was amplified using custom barcoded primers 
and sequenced as described previously using an Illumina MiSeq sequencer [21]. The 
490 samples were divided into three sequencing runs to increase the per sample 
sequencing depth. Although the same percentage of samples from the three groups 
were represented on each sequencing run, samples were randomly assigned to the 
sequencing runs to avoid confounding our analysis based on diagnosis or 
demographics. 
Sequence Curation. The 16S rRNA gene sequences were curated using the mothur 
software package (v1.36), as described previously [21, 22]. Briefly, paired-end reads 
were merged into contigs, screened for quality, aligned to SILVA 16S rRNA sequence 
database, and screened for chimeras. Sequences were classified using a naive 
Bayesian classifier trained against a 16S rRNA gene training set provided by the 
Ribosomal Database Project (RDP) [23]. Curated sequences were clustered into 
operational taxonomic units (OTUs) using a 97% similarity cutoff with the average 
neighbor clustering algorithm. Species-level classifications for OTUs of interest were 
determined by blasting the predominant sequences within each OTU to the NCBI 16S 
rRNA database. The putative species was only reported for OTUs with greater than 
99% sequence identity to a single species in the database; otherwise the consensus 
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RDP classification was used. The number of sequences in each sample was rarefied to 
10,000 per sample to minimize the effects of uneven sampling. Only the 335 OTUs 
present in at least 5% of samples were included in the feature selection for the random 
forest models. 
Statistical Methods. All statistical analyses were performed using R (v.3.2.0). Random 
Forest models were generated using the AUCRF package [24]. All ROC curves 
presented for random forest models are based on the out-of-bag (OOB) error rates. For 
each model, leave-one-out and 10-fold cross-validations were performed to further 
estimate the generalization error of the model. The AUC of ROC curves were compared 
using the method described by DeLong et al. [25]. The optimal cutoff for the MMT was 
determined using Youden's J statistic [26]. This cutoff was determined using the ROC 
curve for differentiating cancer from normal. Comparisons of sensitivities of FIT and the 
MMT at the same specificity were performed using the method developed by Pepe et al. 
with 1000 bootsrap replicates [27]. All of the aforementioned statistics for analyzing 
ROC curves were performed using the pROC package in R [28]. To control for 
diagnosis while testing the effects of sex on the microbiome we used PERMANOVA as 
implemented in the adonis function in the vegan R package [29]. 
Results 
Complementary detection of lesions by FIT and the microbiota. We characterized 
the bacterial communities of stool samples from 490 patients using 16S rRNA gene 
sequencing. Among these patients, 120 had CRC, 198 had adenomas, and 172 had no 
colonic lesions. In addition to characterizing the bacterial community, we tested each 
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sample for the concentration of hemoglobin using FIT. With these data we compared 
the ability to detect lesions using FIT to using a microbiota-based model. First we 
developed a random forest classification model for differentiating healthy individuals 
from those with adenomas based on the relative abundance of bacterial populations in 
stool. We determined the optimal model using the AUC-RF algorithm for maximizing the 
area under the curve (AUC) of the receiver operating characteristic (ROC) curve for a 
random forest model [24]. The optimal model utilized 22 bacterial populations (Fig. 
3.2A). The vast majority of OTUs in the model (17 out of 22) belonged to the order 
Clostridales, 4 were associated with the genus Bacteroides, and one OTU was 
unclassified at the phylum level (Fig. 3.2B). The AUC for this and subsequent random 
forest models were generated based on the out-of-bag (OOB) probabilities for each 
sample. Additional leave-one-out and 10-fold cross validations showed no significant 
difference in AUC compared to the OOB AUC (Fig. 3.3A). The AUC for the microbiota 
model (0.673) was significantly different from a random assignment (p<0.001), but not 
significantly different from that of FIT (FIT AUC:0.639, p>0.05, Fig. 3.1A). At the 100 
ng/ml cutoff FIT detected 15.7% of adenomas with a specificity of 97.1%. Setting the 
microbiota model to the same 97.1% specificity resulted in 18.2% sensitivity for 
adenomas. When comparing the results of the tests for each sample, only 2.5% of 
adenomas were detected by both tests, while 28.8% were detected by only one of the 
two tests (Fig. 3.1B). Thus, the two tests detected small but distinct subsets of 
adenomas. 
Next we generated a random forest model for differentiating normal individuals from 
those with cancer using the relative abundance of 34 bacterial populations (Fig. 3.4A, 
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Fig. 3.4B). Consistent with previous observations, the bacteria most strongly associated 
with CRC belonged to taxa commonly associated with periodontal disease [18, 30, 31]. 
These include OTUs associated Pophyromonas assaccharolytica (OTU105), 
Fusobacterium nucleatum (OTU264), Parvimonas micra (OTU281), Peptostreptococcus 
stomatis (OTU310), Gemella spp. (OTU356), and an unclassified Prevotella (OTU57) 
(Fig. 3.4C). The ROC curve for the model had an AUC of 0.847, which was similar to 
AUCs reported for other microbiota-based models for CRC [17, 18]. The AUC of this 
model was significantly better than a random assignment (p<0.001), but was 
significantly lower than that of FIT (FIT AUC:0.929, p=0.005, Fig. 3.1C). As with the 
adenoma versus normal model, we confirmed the OOB AUC with leave-one-out cross 
validation and 100 iterations of 10-fold cross validation (Fig. 3.3B). At the manufacturer 
recommended cutoff of 100 ng/ml FIT detected 75.0% of cancers with a specificity of 
97.1%. At the same specificity the microbiota model detected 51.7% of cancers. 
Although more cancers were detected by FIT, the microbiota model was able to detect 
33.3% of cancers missed by FIT (Fig. 3.1D). 
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Figure 3.1. Microbiota-based models can complement FIT. (A,C) ROC curves for 
distinguishing healthy patients from those with adenoma (A) or cancer (C) based on FIT 
or a microbiota-based random forest model. Open circles show the sensitivity and 
specifity of FIT with a 100 ng/ml cutoff. Black points show the sensitivity and specificity 
of the microbiota-based models at the chosen cutoffs. (B,D) Results of FIT and a 
microbiota-based model for each adenoma (B) or cancer (D) sample. Dotted lines 
represent the cutoffs for each test. Points are shaded based on whether the lesion was 
detected by both tests (black), one of the two tests (grey), or neither test (white). 
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Figure 3.2. Random forest feature selection for detecting adenomas. (A) Change in 
AUC with varying number of variables in the random forest model. The model with the 
highest AUC contained 22 OTUs. (B) Importance of each OTU in the model as 
measured by mean decrease accuracy when the OTU is removed from the model. (C) 
Relative abundance of the most discriminatory OTUs in adenoma and normal samples. 
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Figure 3.3. Cross validation of OTU random forest models. ROC curves for the (A) 
adenoma versus normal OTU model and (B) cancer versus normal OTU model based 
on OOB estimates, leave-one-out cross validation, and ten-fold cross validation. 
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Figure 3.4. Random forest feature selection for detecting cancers. (A) Change in 
AUC with varying number of variables in the random forest model. The model with the 
highest AUC contained 34 OTUs. (B) Importance of each OTU in the model as 
measured by mean decrease accuracy when the OTU is removed from the model. (C) 
Relative abundance of the most discriminatory OTUs in cancer and normal samples. 
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Multitarget Microbiota Test for colonic lesions. Many of the adenomas and some of 
the carcinomas were detected by the microbiota models, but not FIT, suggesting that 
the two screening methods could complement each other if combined into a single test. 
Based on these observations, we developed a random forest model using both the 
microbiota and FIT that would differentiate normal individuals from those with any type 
of colonic lesion (i.e. adenoma or carcinoma). The optimal model, referred to as the 
Multitarget Microbiota Test (MMT), used the relative abundances of 23 OTUs and the 
concentration of hemoglobin as determined by FIT. Of those OTUs, 16 were members 
of the Firmicutes phylum, including 3 from the Ruminococcaceae family and 10 from the 
Lachnospiraceae family (Fig. 3.5). Three OTUs were associated with the genus 
Bacteroides. The remaining OTUs were associated with Porphyromonas, 
Parabacteroides, Collinsella, and Enterobacteriaceae. The OTU associated with 
Porphyromonas was most closely related to Porphyromonas asaccharolytica, which has 
been previously shown to be predictive of CRC [17, 18, 32]. Interestingly the majority of 
OTUs used in the model, especially the Lachnospiraceae, were enriched in normal 
patients (Fig. 3.5), suggesting that a loss of beneficial organisms in addition to the 
emergence of pathogens may be indicative of CRC development. As with the previous 
random forest models we performed leave-one-out cross validation and 100 iterations of 
10-fold cross validation and found no difference in AUC compared to the OOB 
estimates (Fig. 3.6). 
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Figure 3.5. Bacterial OTUs in MMT. (left) Importance of each OTU used in the MMT 
as measured by the mean decrease in the Gini index when the OTU is removed from 
the model. (right) Stripchart of the relative abundances of each OTU in the MMT with 
black lines at the medians. 
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Figure 3.6. Cross validation of MMT. ROC curves for the MMT model based on OOB 
estimates, leave-one-out cross validation, and ten-fold cross validation. 
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Comparing MMT to FIT. To determine whether microbiota sequence data could be 
used to complement FIT, we compared the performance of the MMT to FIT. For 
differentiating any lesions from normal, the AUC for the MMT was significantly higher 
than FIT (MMT AUC:0.829, FIT AUC:0.749, p<0.001, Fig. 3.7A). Subdividing the 
lesions, detecting adenomas by the MMT (AUC:0.755) was significantly better than FIT 
(AUC:0.639, p<0.001), but not for differentiating cancer from normal (MMT AUC:0.952, 
FIT AUC:0.929, p=0.09). To generate a categorical prediction from the MMT, we 
determined the model's optimal threshold for detecting cancer (0.57 probability of a 
lesion) using Youden's J statisitc [26]. Samples scoring above this cutoff were classified 
as lesions, and those below the cutoff were classified as normal. We then compared the 
sensitivity and specificity of the MMT to those of FIT using a threshold of 100 ng/ml of 
hemoglobin. At these cutoffs the MMT detected 91.7% of cancers and 45.5% of 
adenomas compared to 75.0% and 15.7% for FIT (Table 1, Fig. 3.7B, Fig. 3.7C). When 
adenomas and cancers were pooled together, the MMT detected 62.9% of lesions, 
while FIT only detected 38.1%. However, the increased sensitivity of the MMT was 
accompanied by a decrease in specificity (90.1%) compared to FIT (97.1%). 
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Figure 3.7. Comparing MMT to FIT. (A) ROC Curves for the MMT (solid lines) or FIT 
(dashed lines) for distinguishing normal from any lesion (dark red), normal from cancer 
(red) and normal from adenoma (orange). Filled dots show the sensitivity and specificity 
of the MMT at the optimal cutoff (0.622). Open dots show the sensitivity and specificity 
of FIT at the 100 ng/ml cutoff. (B,C) Stripcharts showing the results for FIT (B) and the 
MMT (C). Dashed lines show the cutoff for each test. Points with a FIT result of 0 are 
jittered to improve visibility. 
1.0 0.8 0.6 0.4 0.2 0.0
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Se
ns
itiv
ity
Specificity
A
MMT−Les. vs Norm.: 0.829
FIT−Les. vs Norm.: 0.749
MMT−Canc. vs Norm: 0.952
FIT−Canc. vs Norm.: 0.929
MMT−Ade. vs Norm.: 0.755
FIT−Ade. vs Norm.: 0.639
●
●
●
●
●
●
●
●
●
●
●
●
●●●
●
●
●●
●●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●●●
●
●
●
●● ●
●
●
●
●● ●●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●● ●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
Normal Adenoma Cancer
0
1
10
10
0
10
00
FI
T 
Re
su
lt (
ng
/m
l)
B
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
● ●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
M
M
T 
Pr
ob
ab
ilit
y o
f L
es
ion
C
Normal Adenoma Cancer
		 69	
Diagnosis Fecal Immunochemical Test Multitarget Microbiota Test 
    True Positives 
Sensitivity 
(95% CI) 
True 
Positives 
Sensitivity 
(95% CI) 
Cancer n=120 90 75.0 (67.5-82.5) 110 91.7 (86.7-958) 
Adenoma n=198 31 15.7 (10.6-20.7) 90 45.5  (38.4-52.5) 
Any Lesions n=318 121 38.1 (32.7-43.4) 200 62.9 (57.2-67.9) 
            
    True Negatives 
Specificity 
(95% CI) 
True 
Negatives 
Specificity 
(95% CI) 
Normal n=172 167 97.1 (94.2-99.4) 155 90.1 (85.5-94.2) 
 
Table 3.1. Sensitivities and specificities for FIT and MMT. The 95% confidence 
intervals were computed with 2000 stratified bootstrap replicates. 
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To better understand the relationship between the MMT and FIT, we compared the 
results of the two tests for each sample (Fig. 3.8A). All but one of the samples that 
tested positive by FIT also tested positive by the MMT. However the MMT was able to 
detect 70.0% of cancers and 37.7% of adenomas that FIT had failed to detect, while 
maintaining a specificity of 92.8% (Fig. 3.8B). This result demonstrated that 
incorporation of data from a subject's microbiota could complement FIT to improve its 
sensitivity. 
To make a fairer comparison of the sensitivities of these two tests, we reduced the 
cutoff for FIT to 7 ng/ml to match the 90.1% specificity of the MMT. At the lower cutoff 
for FIT there was no significant difference in sensitivity for cancer between the two tests 
(p=0.2), but the MMT remained significantly more sensitive for detecting adenomas 
(p=0.02) and all lesions grouped together (p=0.04, Fig. 3.9). 
The purpose of screening is to identify asymptomatic individuals with early stage 
disease (i.e., true positives). Therefore, we estimated the number of true positives 
captured through FIT and MMT in the recommended screening population in the United 
States (adults ages 50-75 years). The prevalence of lesions in an average-risk 
population was obtained through a previously published meta-analysis [33]. Based on 
sensitivities of FIT and MMT in our dataset, we estimate that MMT would detect 
approximately 40 thousand additional cancers, 1.3 million additional advanced 
adenomas, and 5.1 million additional non-advanced adenomas compared to using FIT 
(Table 2). Thus the improved sensitivity of the MMT would increase the total number of 
true positives identified in the recommended screening population of the United States 
by approximately 6.5 million. However, due to the lower specificity of MMT, it would also 
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result in an estimated 4.3 million additional false positives compared to FIT. Further 
studies would be needed to determine whether detection of 6.5 million additional lesions 
(mostly non-advanced adenomas) would outweigh the added cost of 4.3 million 
additional false positives. 
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Figure 3.8. Relationship between FIT and MMT for each sample. (A) Scatterplot of 
MMT and FIT results for each sample. Dashed lines show the cutoff for each test. 
Points with a FIT result of 0 are jittered to improve visibility. (B) Stripchart of MMT 
results for samples separated by binary FIT result. 
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Figure 3.9. Sensitivities for FIT and MMT for each stage of tumor development 
with matching specificities. The cutoff for FIT was reduced to 7 ng/ml to match the 
specificity of the MMT. Sensitivities were compared using the method proposed by 
Pepe et al. (* = p<0.05, 1000 bootstrap replicates). 
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Condition Prevalence 
Number of Persons, 
ages 50-75 years, 
with Condition 
True Positives 
identified by FIT 
True Positives 
identified by 
MMT 
     
Cancer 0.3% 241,483 181,112 221,359 
Advanced 
Adenoma 5.7% 4,588,174 883,960 2,188,854 
Non-advanced 
Adenoma 17.7% 14,247,488 1,600,841 6,723,534 
*Number of persons in the United States in 2010, 50-75 years of age, was 80,494,283. 
 
Table 3.2. Estimated number of true positives detected in average risk population. 
Number of true positives identified through FIT and MMT in the United States in adults 
50-75 years of age, based on published estimates of CRC prevalence. The sensitivities 
for FIT (100 ng/ml cutoff) on advanced and non-advanced adenomas were 19.3% and 
11.2%, respectively. 
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Effect of patient characteristics on model performance. Previous studies have 
identified differences in diagnostic test performance for certain demographic groups or 
for people taking certain medications [34–36]. Therefore we tested whether the MMT 
performance differed between patient populations. We found no difference in model 
performance according to age, BMI, NSAID usage, diabetes, smoking, or previous 
history of polyps (all p>0.05). However the model was significantly better at 
differentiating normal from lesion for females than for males (p=0.02; Fig. 3.10). For 
females the model detected 63.6% of lesions with a specificity of 94.6%. For males the 
model detected 64.5% of lesions with a much lower specificity of 82%. The MMT 
detected 51.2% of adenomas in females and 44.9% in males. Consistent with the lower 
specificity for males, the MMT had a higher sensitivity for cancer among males (98.5%) 
than females (82.7%). The discrepancy appeared to be due to differences in FIT results 
rather than differences in the microbiome. After correcting for diagnosis, there was a 
significant effect of sex on FIT result (p=0.006, two-way ANOVA), but not on the overall 
structure of the microbiome (PERMANOVA: p=0.07). The lower specificity and higher 
sensitivity for cancer among males is consistent with previous observations that males 
have a higher positive rate for FIT [34, 35]. 
We have previously shown that incorporating patient metadata into microbiome-based 
diagnostic models can improve screening accuracy [17]. To test whether the same was 
true for the MMT we generated a random forest model that combined patients' age, 
BMI, sex, and smoking status with the OTUs and FIT result from the MMT. The AUC of 
the ROC curve for this model (0.869) was not significantly different from that of the MMT 
(AUC: 0.829, p=0.11, Fig. 3.11). When the model with patient metadata was set to the 
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same specificity as the MMT (90.1%), it did not improve the sensitivity for lesions 
(63.4%) compared to MMT (62.9%, p=0.9). Thus, contrary to our previous findings, 
incorporation of patient metadata did not significantly improve the MMT. 
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Figure 3.10. MMT performance by sex. ROC curves (left) and stripchart (right) of 
MMT results separated by sex. 
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Figure 3.11. MMT with patient metadata. ROC curves for distinguishing normal from 
lesion using FIT, the MMT, or the MMT with metadata. 
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Discussion 
We confirmed previous findings that the gut microbiota can be used to differentiate 
healthy individuals from those with colonic lesions. Although FIT was better at detecting 
cancers than a model using only the microbiota, microbiota-based models detected a 
subset of lesions that were not detected by FIT. This suggested that the two methods 
could complement each other. Based on this observation we developed a cross-
validated random forest model that combined both FIT and the microbiota to detect 
colonic lesions. The resulting MMT had higher sensitivity than FIT for detecting lesions, 
especially adenomas. The MMT was also able to detect the majority of cancers missed 
by FIT. However, the increased sensitivity of MMT was accompanied by a decrease in 
specificity compared to FIT. With a false positive rate more than three times higher than 
FIT (9.9% versus 2.9%), an annual MMT would result in more colonoscopies than using 
FIT as the primary screening test. However, the higher sensitivity of the MMT might 
make it possible to reduce the frequency of screening, thereby offsetting the difference 
in the number of colonoscopies. Additional studies would be needed identify the 
appropriate screening inverval and to determine whether the increased number of true 
positives identified by MMT justify the increased number of false positives. 
It was recently shown that when FIT was combined with host-associated DNA 
biomarkers, the ability to detect adenomas and carcinomas was significantly improved 
over FIT alone [2]. The sensitivity of the host-associated DNA screen was 92.3% for 
cancer and 42.4% for adenomas with a specificity of 89.8%, all very similar to what we 
observed with our MMT. Such results support the assertion that because of the large 
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interpersonal variation in markers for adenomas and carcinomas, it is necessary to 
employ a panel of biomarkers and to use a model that integrates the biomarkers. The 
accuracy of our model may be further improved by incorporating additional indicators 
such as host-associated biomarkers or those targeting specific genes involved in the 
underlying mechanism of tumorigenesis such as bacterial toxins [15, 16, 18]. More 
generally, predictive and diagnostic models for other diseases with a microbial etiology 
may benefit from a similar approach. For example, we recently demonstrated the ability 
to detect Clostridium difficile infection based on the composition of the microbiota [37]. 
Such models are likely to be useful as microbiota sequencing gains traction as a tool for 
characterizing health. 
Surprisingly most of the OTUs that work well for identifying cancers, including 
Fusobacterium nucleatum (OTU264), Peptostroptococcus stomatis (OTU310), and 
Parvimonas micra (OTU281), were excluded from the MMT. This is likely due to these 
OTUs being positively correlated with FIT (all p<0.001, Spearman correlation), meaning 
they add little information when used in combination with FIT. Instead the MMT is 
enriched for OTUs that help detect adenomas. Thus the MMT model relies primarily on 
FIT for detecting cancer, and uses the microbiota to help identify adenomas 
undetectable by FIT alone. It is also interesting that most of the OTUs used in the MMT 
were enriched in normal individuals, suggesting that a loss of beneficial organisms in 
addition to the emergence of pathogens may be important for colorectal cancer 
development. Many of the OTUs that were depleted in patients with lesions belonged to 
the Ruminococcoaceae and Lachnospiraceae families, which contain the predominant 
producers of butyrate, a short-chain fatty acid with anti-inflammatory and anti-
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tumorigenic properties [38–41]. Likewise Zeller et al. observed a depletion of a potential 
butyrate-producing Eubacterium spp. in patients with CRC [18]. Loss of butyrate or 
other anti-inflammatory microbial metabolites may contribute to CRC development. 
These possibilities highlight the need for longitudinal studies to better understand how 
changes to an individual's microbiome or the metabolic profile of the gut might 
predispose them to CRC. 
Like other groups, we noticed that the microbiota of CRC patients contained higher 
levels of bacterial taxa traditionally thought of as oral pathogens, including 
Fusobacterium, Porphyromonas, Peptostreptococus, Gemella, Parvimonas, and 
Prevotella. Periodontal pathogens have been shown to promote the progression of oral 
cancer [42]. Therefore it is possible that these taxa could influence the progression of 
CRC by a similar mechanism. These observation may warrant further investigation into 
a potential link between periodontal disease and CRC. Furthermore, since the structure 
of an individual's oral microbiome is correlated with that of the gut [43], alterations in the 
oral community could potentially be a proxy for ongoing or future changes to the gut 
community. 
Although it is exciting that the addition of the microbiota can improve the sensitivity of 
FIT, further validation is needed prior to clinical adoption. This represents the largest 
cohort to date, but still only consists of 490 patients. In contrast, the cohort used to 
validate the Multitarget stool DNA test included 9,989 subjects. Development of a larger 
cohort will allow us to apply the MMT to a separate validation set. It is also unclear how 
sensitive the MMT is to variation in sample preparation and processing. Many of the 
samples included in the current study were collected 1-2 weeks after the subjects’ 
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colonoscopy. A previous study showed that the microbiome quickly returns to normal 
following colonoscopy [20]. Likewise we found no difference in the microbiome between 
samples collected prior to or after colonoscopy (PERMANOVA: p=0.45). Regardless, 
we would have greater confidence in the predictive potential of the microbiota if all 
samples were collected prior to colonoscopy. Despite these shortcomings, the ability to 
improve the sensitivity of detecting adenomas suggests that further methods 
development and validation are warranted. 
Conclusions 
Our findings demonstrate the potential for combining the analysis of a patient's 
microbiota with conventional stool-based tests to improve CRC detection. Using the 
random forest algorithm it was possible to interpret FIT results in the context of the 
microbiota. The MMT had higher sensitivity for lesions, especially at early stages of 
tumorigenesis. Moreover the model detected the majority of cancers that FIT was 
unable to detect. The shortcoming of the MMT is its lower specificity. However, the 
potential value of the MMT is its higher sensitivity, which is the purpose of preventive 
screening – finding lesions earlier so that cancer would be avoided. 
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CHAPTER 4: 
DNA from fecal immunochemical test can replace stool for 
microbiota-based colorectal cancer screening 
The contents of this chapter have been submitted for publication as: 
Baxter NT, Koumpouras CC, Ruffin MT IV, Rogers MAM, Schloss PD. (2016).  DNA 
from fecal immunochemical test can replace stool for microbiota-based colorectal cancer 
screening.  BMC Cancer (under review). 
 
 
Abstract 
There is a significant demand for colorectal cancer (CRC) screening methods that are 
noninvasive, inexpensive, and capable of accurately detecting early stage tumors. It has 
been shown that models based on the gut microbiota can complement the fecal occult 
blood test and fecal immunochemical test (FIT). However, a barrier to microbiota-based 
screening is the need to collect and store a patient's stool sample. Using stool samples 
collected from 404 patients we tested whether the residual buffer containing 
resuspended feces in FIT cartridges could be used in place of intact stool samples. We 
found that the bacterial DNA isolated from FIT cartridges largely recapitulated the 
community structure and membership of patients' stool microbiota and that the 
abundance of bacteria associated with CRC were conserved. We also found that 
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models for detecting CRC that were generated using bacterial abundances from FIT 
cartridges were equally predictive as models generated using bacterial abundances 
from stool. These findings demonstrate the potential for using residual buffer from FIT 
cartridges in place of stool for microbiota-based screening for CRC. This may reduce 
the need to collect and process separate stool samples and may facilitate combining 
FIT and microbiota-based biomarkers into a single test. Additionally, FIT cartridges 
could constitute a novel data source for studying the role of the microbiome in cancer 
and other diseases. 
Background 
Although colorectal cancer (CRC) mortality has declined in recent decades, it remains 
the second leading cause of death among cancers in the United States [1]. Early 
detection of CRC is critical since patients whose tumors are detected at an early stage 
have a greater than 90% chance of survival [1]. However more than a third of 
individuals for whom screening is recommended do not adhere to screening guidelines 
[2]. The high cost and invasive nature of procedures, such as colonoscopy and 
sigmoidoscopy are barriers for many people [3, 4]. Unfortunately non-invasive tests, 
such as the guaiac fecal occult blood test (gFOBT), fecal immunochemical test (FIT), 
and the multitarget DNA test fail to reliably detect adenomas [5, 6] (e.g., sensitivity for 
nonadvanced adenomas is 7.6% for FIT and 17.2% for the DNA test). Thus, there is a 
need for novel non-invasive screening methods with improved sensitivity for early stage 
colonic lesions. 
Several studies have demonstrated the potential for the gut microbiota to be used to 
detect CRC [7–10]. Moreover, we and others have shown that combining microbiota-
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analysis with conventional diagnostics, like gFOBT and FIT, can significantly improve 
the detection of colonic lesions over either method by itself [7, 8, 10]. One limitation of 
microbiota-based CRC screening is the need to collect and process separate stool 
samples for microbiota characterization. Given the widespread use of FIT to collect 
specimens for screening, the ability to use the same sample for microbiota 
characterization could make processing more efficient and less expensive. We 
hypothesized that the small amount of fecal material contained in FIT sampling 
cartridges was sufficient to perform both hemoglobin quantification and microbiota 
characterization. To test this hypothesis, we isolated bacterial DNA from the residual 
buffer of OC-Auto® FIT cartridges (Polymedco Inc.) that had already been used for 
quantifying fecal hemoglobin concentrations. We then compared the bacterial 
composition of the FIT cartridge to that of DNA isolated directly from a patient's stool 
sample and assessed the ability of FIT cartridge-derived DNA to be used for microbiota-
based CRC screening. 
Methods 
Study Design / Diagnoses / Stool Collection. Stool samples were obtained through 
the Great Lakes-New England Early Detection Research Network. Patients were 
asymptomatic, at least 18 years old, willing to sign informed consent, able to tolerate 
removal of 58 mL of blood, and willing to collect a stool sample. Patient age at the time 
of enrollment ranged from 29 to 89 with a median of 60 years. Patients were excluded if 
they had undergone surgery, radiation, or chemotherapy for current CRC prior to 
baseline samples or had inflammatory bowel disease, known hereditary non-polyposis 
CRC, or familial adenomatous polyposis. Patient diagnoses were determined by 
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colonoscopic examination and histopathological review of any biopsies taken. 
Colonoscopies were performed and fecal samples were collected in four locations: 
Toronto (Ontario, Canada), Boston (Massachusetts, USA), Houston (Texas, USA), and 
Ann Arbor (Michigan, USA). Stool samples were packed in ice, shipped to a processing 
center via next day delivery and stored at -80˚C. Fecal material for FIT was collected 
from frozen stool aliquots using OC-Auto® FIT sampling bottles (Polymedco Inc.), 
processed using an OC-Auto Micro 80 automated system (Polymedco Inc.), and stored 
at -20C. The University of Michigan Institutional Review Board approved this study, and 
all subjects provided informed consent. 
16S rRNA gene sequencing. Processed FIT samples were thawed, and 100 µl of 
buffer were withdrawn by pipette for DNA extraction. DNA was isolated from FIT 
samples or matching stool samples using the PowerSoil-htp 96 Well Soil DNA isolation 
kit (MO BIO Laboratories) and an epMotion 5075 automated pipetting system 
(Eppendorf). The V4 region of the bacterial 16S rRNA gene was amplified using custom 
barcoded primers and sequenced as described previously using an Illumina MiSeq 
sequencer [11]. The 16S rRNA gene sequences were curated using the mothur 
software package, as described previously [11, 12]. Curated sequences were clustered 
into operational taxonomic units (OTUs) using a 97% similarity cutoff with the average 
neighbor clustering algorithm. Sequences were classified using a naive Bayesian 
classifier trained against a 16S rRNA gene training set provided by the Ribosomal 
Database Project (RDP) [13]. Species-level classifications for OTUs of interest were 
determined by using blastn to compare the predominant sequence within each OTU to 
the NCBI 16S rRNA database. The putative species was only reported for OTUs with 
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greater than 99% sequence identity to a single species in the database; otherwise the 
consensus RDP classification was used. 
Statistical Methods. All statistical analyses were performed using R (v.3.2.0). Random 
forest models were generated using the AUC-RF algorithm for feature reduction and 
maximizing model performance [14]. The most predictive OTUs were determined based 
on mean decrease in accuracy when removed from the model. The area under the 
curve (AUC) of receiver operator characteristic (ROC) curves were compared using the 
method described by DeLong et al. [15] as implemented in the pROC R package [16]. 
Results 
DNA was isolated and 16S rRNA gene sequencing was performed on stool aliquots and 
the residual buffer of paired OC-Auto® FIT sampling cartridges from 404 patients. 
Among these patients, 101 had CRC, 162 had adenomas, and 141 had no colonic 
lesions. First, we tested whether the bacterial community profiles from FIT cartridges 
recapitulated their stool counterparts. First, we compared the number of OTUs shared 
within FIT/stool pairs from the same patient to the number of OTUs shared between 
patients (Fig. 4.1A). FIT cartridges and stool from the same patient (red line) had 
significantly more bacterial populations in common than those taken from different 
patients (p<0.001, two-sample Kolmogorov-Smirnov test), indicating that community 
membership was conserved within patients across stool and FIT cartridges. Second, we 
calculated the similarity in community structure between samples using 1-thetaYC index 
[17]. This metric compares the presence or absence of bacterial populations and their 
relative abundance. The bacterial community structure of stool and FIT samples from 
the same patient (red line) were significantly more similar to each other than to stool or 
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FIT from other patients (Fig. 4.1B, p<0.001). Finally, we used a Mantel test to determine 
whether the patient-to-patient thetaYC distances among stool samples were correlated 
with the patient-to-patient thetaYC distances among FIT cartridges. We found that there 
was a significant correlation (Mantel test r=0.525, p<0.001), suggesting that the inter-
patient variation in community structure between the stool samples of patients was 
conserved in samples from FIT cartridges. 
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Figure 4.1. Bacterial community structure from FIT cartridge recapitulates stool. 
Density plots showing distribution of the number of shared OTUs (A) and community 
similarity (B) between groups of samples (* p<0.001 two-sample Kolmogorov-Smirnov 
Test). 
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Next, we observed a significant correlation between the abundance of each genus in 
the paired FIT cartridge and stool samples (Fig. 4.2A, Spearman rho: 0.699, p<0.001). 
This suggested that the abundance of bacterial genera was conserved. This correlation 
was especially strong when comparing only the 100 most abundant genera from stool 
(Spearman rho: 0.886, p<0.001). Several bacterial species have been repeatedly 
associated with CRC, including Fusobacterium nucleatum, Porphyromonas 
asaccharolytica, Peptostreptococcus stomatis, and Parvimonas micra [8–10, 18]. As 
expected, the abundance of these species in stool was significantly correlated with their 
abundance in matched FIT cartridges (all p<0.001, Spearman rho ≥0.352)(Fig. 4.2B). 
We observed some biases in the abundance of certain taxa. In particular, the genus 
Pantoea was detected in 399 of the 404 FIT cartridges with an average abundance of 
2.4%, but was only detected in 1 stool sample. The genus Helicobacter was detected in 
172 FIT cartridges, but only 10 stool samples. Likewise several genera of Actinobacteria 
were more abundant in stool samples compared to FIT. Notwithstanding these few 
exceptions, the abundance of the vast majority of genera were well conserved between 
stool and FIT cartridges. Overall, these findings suggested that that the overall bacterial 
community structure and the abundance of specific taxa in FIT cartridges and stool 
were similar. 
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Figure 4.2. Bacterial populations conserved between stool and FIT cartridge. (A) 
Scatterplot of the average relative abundance of each bacterial genus in stool and FIT 
cartridges colored by phylum. (B) Scatterplots of the relative abundances of 4 species 
frequently associated with CRC. All correlations were greater than 0.35 (all p<0.001). 
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We tested whether the bacterial relative abundances we observed from FIT cartridges 
could be used to differentiate healthy patients from those with carcinomas using random 
forest models as we did previously using intact stool samples [10]. Using DNA from the 
FIT cartridge, the optimal model utilized 28 OTUs and had an AUC of 0.831 (Fig. 4.3A). 
There was not a significant difference in the AUC for this model and the model based on 
DNA isolated directly from stool, which used 32 OTUs and had an AUC of 0.853 
(p=0.41). Furthermore, the probabilities of individuals having lesions was correlated 
between the models generated using DNA isolated from the FIT cartridges and stool 
samples (Spearman rho: 0.633, p<0.001, Fig. 4.3B). We also generated random forest 
models for differentiating healthy patients from those with any type of lesions (i.e. 
adenoma or carcinoma). There was not a significant difference in AUC between the 
stool-based model with 41 OTUs (AUC=0.700) and the FIT cartridge-based model with 
41 OTUs (AUC=0.686, p=0.65, Fig. 4.3C). Again, the probabilities of individuals having 
lesions according to the two models were significantly correlated (Spearman rho: 0.389, 
p<0.001 Fig. 4.3D). These findings demonstrated that models based on bacterial DNA 
from FIT cartridges were as predictive as models based on DNA isolated directly from 
stool.
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Figure 4.3. Microbiota-based models from FIT cartridge DNA are as predictive as 
models from stool. (A) ROC curves for distinguishing healthy patients from those with 
cancer using using microbiota-based random forest models using DNA from FIT 
cartridges or stool. (B) Probability of having cancer for each patient according to 
microbiota-based models from A. (C) ROC curves for distinguishing patients with 
adenomas or carcinomas from healthy patients using microbiota-based random forest 
models using DNA from FIT cartridges or stool. (D) Probability of having a lesion for 
each patient based on the models from C. 
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Discussion 
Bacterial DNA isolated from the residual buffer of FIT cartridges recapitulated the 
community structure and membership of patients' stool microbiota. FIT/stool pairs 
collected from the same patient were significantly more similar to each other than 
samples from different patients and the inter-patient differences in stool microbiota 
structure were conserved in FIT cartridge-derived microbiota. More importantly, random 
forest models generated using bacterial abundances from FIT cartridge-derived and 
stool-derived DNA were equally predictive for differentiating healthy patients from those 
with adenomas and carcinomas. 
Sinha et al. compared a variety of sampling and storage methods for fecal samples to 
be used for microbiome analyses [19]. They found reproducible biases according to 
sampling method and time at ambient temperature. Likewise, we observed biases in the 
abundance certain bacterial populations in FIT cartridges compared stool. For example, 
an OTU associated with Pantoea was found in 98.8% of FIT cartridge samples and only 
0.2% of stool samples. There are several possible explanations for this result. It is 
possible that because the biomass contained in the FIT cartridges is considerably lower 
than that in stool, the analysis was more sensitive to contaminants in our reagents or 
the FIT cartridge [20]. Alternatively, storage conditions could have played a role in 
biasing the relative abundances of certain genera. The feces in the FIT cartridges spent 
more time exposed to ambient temperatures in order to be analyzed for hemoglobin 
concentration. Therefore it is possible that certain bacterial populations, especially 
aerobes, were able to grow. Considering Pantoea is rarely found in human feces and is 
more commonly found in soil, plant surfaces, and air we suspect that it was a 
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contaminant. Regardless of the source of this and the other suspicious populations, any 
biases were limited since the random forest feature selection process did not select 
these populations and did not affect the ability to detect CRC from FIT cartridge-derived 
DNA. 
Conclusions 
This could reduce the need to collect and process separate stool samples, decreasing 
the cost of screening. It may be possible to use FIT cartridges rather than separate stool 
samples for future studies on the role of the gut microbiota and cancer. Samples 
collected from patients who undergo annual FIT screening could be used to monitor 
temporal changes in a patient's microbiota, making it possible to detect shifts toward a 
disease-associated microbiota. Since FIT cartridges are currently used for CRC 
screening, our findings may facilitate large-scale validations of microbiota-based 
screening methods. 
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CHAPTER 5: Discussion 
The preceding chapters demonstrate the potential for using the gut microbiota for 
detecting CRC. In them we showed that the composition of the gut microbiota can 
potentially influence an individual’s susceptibility to CRC, that shifts in microbiota 
composition can be used to predict the presence of lesions, and that microbiota-based 
screening can be combined with fecal immunochemical test into a single test with 
improved sensitivity for colonic lesions. This chapter includes a summary of the findings 
from the preceding chapters, discussion on the implications of those findings, and the 
next steps for microbiota-based CRC screening. 
Summary and implications of Chapter 2 
In Chapter 2, we used a germ-free mouse model to test the influence of microbiota 
structure on colon tumorigenesis. We initially hypothesized that mice inoculated with 
human cancer-associated microbiota would develop more tumors than mice who 
received microbiota from healthy human donors. There was evidence supporting this 
hypothesis. We had already shown that germ-free mice that received cancer-associated 
microbiota from other mice developed more tumors than mice inoculated with healthy 
mouse microbiota [1]. Other groups had reportedly transferred other disease 
phenotypes from humans to mice through microbiota transfer [2–4]. However, the same 
did not hold true in our experiment, as there was no difference in tumor burden between 
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mice who received a healthy or cancer-associated microbiota. There were several 
potential explanations for the lack of phenotype transfer. Chief among them is the 
inability to fully recapitulate the microbiota structure of the human donor. In an extreme 
example, one human donor’s microbiota was composed of 70% Fusobacteria, however 
the mice who received that microbiota had no detectable Fusobacteria in their stool. 
Even if there had been completely transfer of the donor’s microbiota structure, there 
was no guarantee that the species associated with CRC in humans would be able to 
accelerate tumorigenesis in mice. 
Nonetheless, the study provided valuable insights into the microbiota’s role in CRC and 
potential use as screening tool. The most striking observation from this study was that 
the amount of tumors mice developed was strongly associated with the structure of the 
microbiota prior to undergoing the chemically induced model. This was a new finding, as 
previously we had only associated the endpoint microbiota with the severity of disease 
[1]. This suggested that the structure of the microbiota may influence an individual’s 
susceptibility to tumorigenesis, which opens the possibility of using the microbiota, not 
only to detect CRC, but to predict an individual’s risk of developing tumors. 
The predicted metagenomes from this study showed a negative correlation between 
butyrate producing genes and the number of tumors mice developed. This supports 
epidemiological data in which a high fiber diet and high butyrate levels are associated 
with lower risk of CRC [5, 6] and studies showing that butyrate protects against colon 
tumorigenesis [7–10]. On the other hand, genes potentially involved in mucin 
degradation were positively correlated with the number of tumors mice developed. 
These findings are consistent with a model in which the balance of pro- and anti-
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inflammatory activities of the microbiota influence and individual’s risk of developing 
CRC. 
Summary and implications of Chapter 3 
In Chapter 3, we confirmed previous studies, showing that the microbiota can be used 
to differentiate individual’s with CRC from those with healthy colons. We expanded upon 
those findings by showing that the microbiota could be used to detect a subset of 
lesions that was distinct from those detected by FIT. Then, we combined microbial 
biomarkers and FIT into a single model that had improved sensitivity for colonic lesions, 
especially at the earliest stages of tumor development, where current noninvasive tests 
are least effective. 
These findings demonstrated the advantage of combining multiple biomarkers into a 
single test. This concept is part of what makes the MT-sDNA test a relatively effective 
screening tool. Our MMT model and the MT-sDNA test have remarkably similar 
specificity and sensitivities for each type of lesion [11]. It is likely that combining the 
host-associated markers in the MT-sDNA with the microbial markers in the MMT would 
further improve screening accuracy. It is also likely that incorporating patient 
characteristics into the model would also improve their accuracy. That was true for our 
models in an earlier study [12], but not for the MMT model. 
Summary and implications of Chapter 4 
In Chapter 4, we took the findings from Chapter 3 one step further. Not only could the 
results from FIT and the microbiota analysis be combined into a single model, but the 
two tests could be physically linked by using the same sampling cartridge for both tests. 
Although the results of this study were not surprising, they could have a profound 
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impact on the way we study the microbiota and colorectal cancer. Thousands of FIT 
cartridges are analyzed in the U.S. every day [13]. If those could be repurposed for 
microbiota research, it could drastically increase the number of samples available for 
studying the microbiota’s role in CRC and many other diseases. Furthermore, FIT 
cartridges are typically performed annually, which means an individual’s microbiota can 
be monitored over time. This could allow for large-scale longitudinal study of the 
microbiota. It would even be possible to study changes in the microbiota that occur 
leading up to the development of tumors. 
The next step for CRC screening 
Monitoring changes to an individual’s microbiota over time may be the most effective 
way to detect disease-associated alterations in the microbiota. The most predictive 
species for adenomas were not the potentially pathogenic species typically associated 
with carcinomas. Instead, patients with adenomas were identified by a lack of potentially 
beneficial organisms, especially the often butyrogenic Lachnospiraceae family. Based 
on the findings from Chapter 2 and other studies, a decrease in butyrate producers 
could lead to an increase in susceptibility to tumorigenesis [7, 8, 10]. However, many 
different bacterial populations were needed even to be weakly predictive for detecting 
adenomas. One potential explanation is that the loss of beneficial organisms is highly 
individual-specific. An underlying theme of human microbiota research is the high level 
of inter-individual variability. If no two individuals have the exactly the same “healthy” 
microbiota, then we cannot expect every individual to have the same deviation from that 
healthy state. 
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With that in mind, the best approach to microbiota-based screening may be to monitor a 
patient’s microbiota over a long period of time, making it easier to detect individual-
specific shifts in the structure of their microbiota. These idiosyncratic changes may be 
the best way to detect subtle, but important shifts that might be indicative of early tumor 
development. Only later in tumor development are there consistent blooms in potential 
pathogens in most individuals. Like many other fields of medicine, microbiota-related 
diseases may require a highly personalized approach to both screening and treatment. 
Potential mechanism for microbiota-mediated tumorigenesis 
Like several other groups, we found that bacteria typically associated with oral cavity 
were among the most enriched in the stool of patients with carcinomas [14–16]. F. 
nucleatum has received the most attention due to its ability to potentiate tumors in a 
mouse model, however P. asaccharolytica was even more enriched in patients with 
CRC in our study. Interestingly another Porphyromonas species, P. gingivalis is capable 
of synergizing with F. nucleatum to promote oral cancer [17]. It is possible that a similar 
mechanism can happen in the gut. Even if no causal link exists, P. asaccharolytica 
shows potential as an effective biomarker for CRC. Likewise Parvimonas micra and 
Peptostreptoccus stomatis have been repeatedly associated with carcinomas as well 
[14, 15, 18]. 
We propose the following as one potential mechanism for the microbiota’s role in CRC. 
First there are perturbations to an individual’s gut microbiota, involving the loss of 
mutualistic species, including a decrease in butyrate production and/or other beneficial 
metabolic activity. These changes could predispose the colon to adenoma formation. 
The altered environment of the adenomatous tissue could allow for F. nucleatum to 
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colonize the distal gastrointestinal tract, binding epithelial cells via its adhesion FadA. 
Then, as it does in the periodontal cavity, F. nucleatum can mediate the binding of other 
oral pathogens, forming a multispecies biofilm [19, 20]. These oral pathogens could 
promote inflammation and the secretion of peptides to sustain their asaccharolytic 
metabolism, as they do in periodontitis [21]. This would lead to cycle in which the oral 
pathogens promote and benefit from an inflamed microenvironment that accelerates the 
progression of tumorigenesis. This mechanisms, though highly speculative, is 
consistent with the changes in microbiota structure that occur over the course of tumor 
development and the known pro-inflammatory and tumorigeneic activity of these 
species in the mouth [22]. 
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